|
rs77375493
|
|
Leukemia, Myelocytic, Acute
|
|
0.900 |
GeneticVariation
|
BEFREE |
JAK2 V617F mutations clustered in AML samples with an aberrant karyotype (p<0.05).
|
17229652 |
2007 |
|
rs77375493
|
|
Leukemia, Myelocytic, Acute
|
|
0.900 |
GeneticVariation
|
BEFREE |
Janus kinase2 V617F</span> was present in 13/162 AML samples (8%): 10/13 transformed MPD, and three apparent de novo AML (one of 12 AML-M6, one of 24 AML-M7, and one AML-M2 - all mixed clonality).
|
16598306 |
2006 |
|
rs77375493
|
|
Leukemia, Myelocytic, Acute
|
|
0.900 |
GeneticVariation
|
BEFREE |
JAK2(V617F) was identified in patients previously diagnosed with a myeloproliferative disorder or acute myeloid leukemia transformed from myeloproliferative disorder, whereas a wild-type genotype was identified in patients with reactive conditions or de novo acute myeloid leukemia.
|
16831057 |
2006 |
|
rs77375493
|
|
Leukemia, Myelocytic, Acute
|
|
0.900 |
GeneticVariation
|
UNIPROT |
None of the AML patients with the JAK2 V617F mutation had a history of previous hematologic disorders.
|
16247455 |
2006 |
|
rs77375493
|
|
Leukemia, Myelocytic, Acute
|
|
0.900 |
GeneticVariation
|
BEFREE |
None of the AML patients with the JAK2 V617F mutation had a history of previous hematologic disorders.
|
16247455 |
2006 |
|
rs77375493
|
|
Leukemia, Myelocytic, Acute
|
|
0.900 |
GeneticVariation
|
BEFREE |
The V617F mutation is present in blood and marrow from a large proportion of patients with classic BCR/ABL-negative chronic myeloproliferative disorders and of a few patients with other clonal hematological diseases such as myelodysplastic syndrome, atypical myeloproliferative disorders, and acute myeloid leukemia.
|
16931578 |
2006 |
|
rs77375493
|
|
Leukemia, Myelocytic, Acute
|
|
0.900 |
GeneticVariation
|
BEFREE |
We screened 79 acute myeloid leukemia (AML) cell lines and found five positive for JAK2 V617F (HEL, MB-02, MUTZ-8, SET-2, UKE-1), 4/5 with histories of MPD/MDS.
|
16408098 |
2006 |
|
rs77375493
|
|
Leukemia, Myelocytic, Acute
|
|
0.900 |
GeneticVariation
|
BEFREE |
V617F was not identified in patients with systemic mastocytosis (n = 28), chronic or acute myeloid leukemia (n = 35), secondary erythrocytosis (n = 4), or healthy controls (n = 160).
|
15920007 |
2005 |
|
rs77375493
|
|
Leukemia, Myelocytic, Acute
|
T |
0.900 |
CausalMutation
|
CLINVAR |
|
|
|
|
rs121912472
|
|
Leukemia, Myelocytic, Acute
|
|
0.810 |
GeneticVariation
|
BEFREE |
Thus our studies provide clues in understanding the leukemogenesis of JAK2 K607N mutation in AML.
|
30521925 |
2019 |
|
rs121912472
|
|
Leukemia, Myelocytic, Acute
|
|
0.810 |
GeneticVariation
|
UNIPROT |
Acute myeloblastic leukaemias in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
|
23970018 |
2013 |
|
rs121912472
|
|
Leukemia, Myelocytic, Acute
|
|
0.810 |
GeneticVariation
|
UNIPROT |
NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology.
|
22138009 |
2011 |
|
rs121912472
|
|
Leukemia, Myelocytic, Acute
|
|
0.810 |
GeneticVariation
|
UNIPROT |
The JAK2 V617F mutation in de novo acute myelogenous leukemias.
|
16247455 |
2006 |
|
rs121912472
|
|
Leukemia, Myelocytic, Acute
|
C |
0.810 |
CausalMutation
|
CLINVAR |
|
|
|
|
rs121913487
|
|
Leukemia, Myelocytic, Acute
|
T |
0.800 |
CausalMutation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
|
rs121913487
|
|
Leukemia, Myelocytic, Acute
|
C |
0.800 |
CausalMutation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
|
rs121913487
|
|
Leukemia, Myelocytic, Acute
|
T |
0.800 |
CausalMutation
|
CLINVAR |
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia.
|
23321257 |
2013 |
|
rs121913487
|
|
Leukemia, Myelocytic, Acute
|
T |
0.800 |
CausalMutation
|
CLINVAR |
Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.
|
23430109 |
2013 |
|
rs121913487
|
|
Leukemia, Myelocytic, Acute
|
C |
0.800 |
CausalMutation
|
CLINVAR |
Mutational landscape of AML with normal cytogenetics: biological and clinical implications.
|
23261068 |
2013 |
|
rs121913487
|
|
Leukemia, Myelocytic, Acute
|
T |
0.800 |
CausalMutation
|
CLINVAR |
Mutational landscape of AML with normal cytogenetics: biological and clinical implications.
|
23261068 |
2013 |
|
rs121913487
|
|
Leukemia, Myelocytic, Acute
|
C |
0.800 |
CausalMutation
|
CLINVAR |
Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.
|
23430109 |
2013 |
|
rs121913487
|
|
Leukemia, Myelocytic, Acute
|
C |
0.800 |
CausalMutation
|
CLINVAR |
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia.
|
23321257 |
2013 |
|
rs121913487
|
|
Leukemia, Myelocytic, Acute
|
C |
0.800 |
CausalMutation
|
CLINVAR |
The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia.
|
23714533 |
2013 |
|
rs121913487
|
|
Leukemia, Myelocytic, Acute
|
C |
0.800 |
CausalMutation
|
CLINVAR |
The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia.
|
23783394 |
2013 |
|
rs121913487
|
|
Leukemia, Myelocytic, Acute
|
T |
0.800 |
CausalMutation
|
CLINVAR |
The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia.
|
23783394 |
2013 |